MaxKatesMD

Urology • Baltimore, MD

Physician

Join to view full profile

Dr. Kates is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kates' full profile

Already have an account?

Office
601 North Caroline Street
Baltimore, MD 21287
Phone+1 410-955-6100

Fax+1 410-614-0789

Education & Training

Johns Hopkins UniversityResidency, Urology, 2013 - 2018
Icahn School of Medicine at Mount SinaiClass of 2012

Certifications & Licensure

MD State Medical License 2015 - 2026
American Board of Urology Urology

Publications & Presentations

PubMed

59 citations
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Jean H. Hoffman-Censits, Kara Lombardo, Vamsi Parimi, Sonia Kamanda, Woonyoung Choi
Applied Immunohistochemistry & Molecular Morphology. 2021-04-23
6 citations
Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer.
Sean A Fletcher, Trinity J Bivalacqua, Otis W Brawley, Max Kates
Urologic Oncology. 2022-05-01
27 citations
Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population–based analysis ...
Meera Chappidi, Max Kates, Michael H. Johnson, Noah M. Hahn, Trinity J. Bivalacqua
Urologic Oncology. 2016-12-01

Journal Articles

Hospitalization and Readmission Costs After Radical Cystectomy in a Nationally Representative Sample: Does Urinary Reconstruction Matter?
Hiten D Patel, Meera R Chappidi, Trinity J Bivalacqua, Gregory A Joice, Phillip M Pierorazio, Max Kates, Nikolai A Sopko, BJU International

Authored Content

Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialAugust 2021

Press Mentions

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024
Patients Talked; We Listened, Studied, and Came up with a Plan to Make It Better. Now We Want to Test ItDecember 12th, 2023
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder CancerAugust 1st, 2022
Join now to see all